A new review finds flavonoid metabolism drives their effects in the body

A new review in the journal Nutraceuticals examines how flavonoids are absorbed, transformed and used by the body, offering an updated look at a group of plant compounds that has drawn sustained interest in nutrition science and in beverage research.

The paper focuses on metabolism and bioavailability, two issues that shape whether flavonoids can produce measurable biological effects after they are consumed. Flavonoids are found in many foods and drinks, including grapes, berries, tea, cocoa and wine. Researchers have long linked them to possible antioxidant, anti-inflammatory and cardiometabolic benefits, but the review makes clear that those effects depend less on the original compound in food than on what happens to it during digestion and after it enters the bloodstream.

According to the review, flavonoids undergo extensive changes in the gastrointestinal tract and in the liver. Enzymes in the small intestine and liver can break them down or attach other chemical groups to them, while gut microbes in the colon can convert them into smaller metabolites. Those metabolites may circulate in the body at higher levels than the original flavonoids and may be more relevant to biological activity.

That point matters because many laboratory studies test native flavonoids at concentrations that may not reflect what human tissues actually encounter after a meal or drink. The review argues that a better understanding of metabolism is needed to interpret earlier findings and to design future studies that are closer to real human exposure.

The authors describe bioavailability as highly variable across different flavonoid classes. Chemical structure plays a central role. Some compounds are absorbed more easily than others, and many are present in foods as glycosides or larger polymers that must first be modified before absorption can occur. Food matrix, dose, timing of intake and differences in gut microbiota also affect how much reaches circulation and in what form.

The review also points to large person-to-person variation. Age, genetics, health status and microbial composition in the gut can all influence metabolic pathways. That helps explain why one person may show a stronger physiological response than another after consuming similar amounts of flavonoid-rich foods or beverages.

For scientists studying wine polyphenols or grape seed extracts, the review provides a framework for judging which compounds are likely to be biologically active in humans and which claims remain too broad. In practical terms, that could affect how researchers approach formulation, dosing and health-related communication around beverages that contain polyphenols. It may also guide future work on whether specific metabolites, rather than parent compounds, should be used as markers in clinical studies.

The paper does not present new clinical trial results. Instead, it synthesizes existing evidence on how flavonoids move through the body and how those pathways may shape their effects on inflammation, oxidative stress, vascular function and other biological targets. By updating that picture, the review adds context to a field where public interest often moves faster than the underlying human evidence.

The findings are especially relevant for sectors that market products with naturally occurring polyphenols. Wine has been one of the most visible examples, but similar questions apply to juices, teas and other plant-based drinks. If beneficial effects depend on metabolites formed after digestion, then product composition alone may not be enough to predict outcomes in consumers.

The review also underscores a broader challenge for nutrition science: compounds that appear promising in cell studies do not always behave the same way in people. Once digestion, microbial transformation and rapid excretion are taken into account, exposure can look very different from what is assumed in simplified models.

That has implications for future research design. Studies may need to measure circulating metabolites more consistently, account for microbiome differences among participants and distinguish between short-term biochemical changes and clinically meaningful health effects. For beverage producers and ingredient developers, the work suggests that scientific support for flavonoid-related benefits will depend increasingly on human metabolism data rather than on raw ingredient content alone.

Although interest in flavonoids remains strong, the review presents a cautious message. Their biological potential is shaped by complex metabolic steps that can enhance, limit or redirect activity after consumption. For researchers working with wine polyphenols and related compounds, that complexity is likely to remain central as they try to connect chemical composition with real effects in the body.